I'm familiar with Frequency Therapeutics and FX-322. It is not a pill, however – it is is an intratympanic injection. The link Colleen posted is the official study page for the most recent FX-322 clinical trial, which is ongoing. Results for this study are expected to be announced in the second quarter of 2021, according to a recent August 12th press release. The topline results were originally anticipated for September 2020. Delay is due to impact of Covid19 on patient enrollment, nothing unusual given the circumstances.
I'm familiar with Frequency Therapeutics and FX-322. It is not a pill, however – it is is an intratympanic injection. The link Colleen posted is the official study page for the most recent FX-322 clinical trial, which is ongoing. Results for this study are expected to be announced in the second quarter of 2021, according to a recent August 12th press release. The topline results were originally anticipated for September 2020. Delay is due to impact of Covid19 on patient enrollment, nothing unusual given the circumstances.
Create an account to connect with other patients and caregivers like you. Ask questions, get answers, and give and get support. Also follow blogs from Mayo Clinic experts.
MayoClinic.org
Is this the trial you are referring to
– FX-322 in Adults With Stable Sensorineural Hearing Loss https://clinicaltrials.gov/ct2/show/NCT04120116
I'm familiar with Frequency Therapeutics and FX-322. It is not a pill, however – it is is an intratympanic injection. The link Colleen posted is the official study page for the most recent FX-322 clinical trial, which is ongoing. Results for this study are expected to be announced in the second quarter of 2021, according to a recent August 12th press release. The topline results were originally anticipated for September 2020. Delay is due to impact of Covid19 on patient enrollment, nothing unusual given the circumstances.
@urgentresearch, thank you for clarifying. Are you involved with this research?
No, but I am involved in monitoring hearing loss clinical trials and new research and so I thought I would pass along an update 🙂
Thank you!